Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-5.88 Insider Own8.61% Shs Outstand49.26M Perf Week-6.69%
Market Cap734.96M Forward P/E- EPS next Y-1.49 Insider Trans-4.07% Shs Float45.01M Perf Month-7.10%
Income-260.15M PEG- EPS next Q-1.28 Inst Own87.73% Short Float9.47% Perf Quarter-18.65%
Sales86.73M P/S8.47 EPS this Y24.79% Inst Trans-3.01% Short Ratio6.79 Perf Half Y-22.01%
Book/sh7.97 P/B1.87 EPS next Y67.08% ROA-37.78% Short Interest4.26M Perf Year-24.03%
Cash/sh6.88 P/C2.17 EPS next 5Y13.60% ROE-60.80% 52W Range11.83 - 28.80 Perf YTD-16.88%
Dividend Est.- P/FCF- EPS past 5Y- ROI-50.46% 52W High-48.19% Beta1.35
Dividend TTM- Quick Ratio3.59 Sales past 5Y72.63% Gross Margin36.92% 52W Low26.12% ATR (14)0.88
Dividend Ex-Date- Current Ratio3.59 EPS Y/Y TTM5.90% Oper. Margin-304.10% RSI (14)32.82 Volatility4.99% 5.44%
Employees344 Debt/Eq0.44 Sales Y/Y TTM-20.90% Profit Margin-299.97% Recom1.42 Target Price39.25
Option/ShortYes / Yes LT Debt/Eq0.32 EPS Q/Q9.76% Payout- Rel Volume0.49 Prev Close14.96
Sales Surprise-33.59% EPS Surprise-9.60% Sales Q/Q-18.37% EarningsMay 08 AMC Avg Volume627.96K Price14.92
SMA20-6.83% SMA50-17.56% SMA200-15.10% Trades Volume309,684 Change-0.27%
Date Action Analyst Rating Change Price Target Change
Mar-11-24Initiated H.C. Wainwright Buy $36
Mar-08-24Upgrade RBC Capital Mkts Sector Perform → Outperform $20 → $35
Mar-06-24Upgrade Leerink Partners Market Perform → Outperform $37
Feb-21-24Resumed Raymond James Outperform $45
Nov-01-23Initiated Stifel Buy $35
Jun-02-23Initiated Robert W. Baird Outperform $42
Jun-23-22Initiated Berenberg Buy $61
Dec-15-21Initiated Wedbush Neutral $29
Oct-19-21Resumed Morgan Stanley Overweight $62 → $50
Jan-06-21Upgrade Raymond James Outperform → Strong Buy $60
May-15-24 11:38AM
May-10-24 02:30PM
May-09-24 03:53PM
07:11AM Loading…
May-08-24 09:56PM
May-01-24 07:05AM
Apr-24-24 07:05AM
Mar-28-24 01:09PM
04:05PM Loading…
Mar-27-24 04:05PM
Mar-18-24 07:00PM
Mar-13-24 08:00AM
Mar-11-24 07:05AM
Mar-08-24 01:29AM
Mar-06-24 11:20PM
Mar-05-24 07:05AM
Feb-29-24 04:57PM
Feb-28-24 11:05AM
Feb-27-24 05:35PM
04:32PM Loading…
Feb-21-24 07:05AM
Feb-17-24 12:07AM
Feb-08-24 09:36AM
Feb-07-24 11:40AM
Jan-31-24 07:05AM
Jan-18-24 09:01PM
Jan-16-24 02:47PM
Jan-10-24 07:05AM
Jan-09-24 06:20PM
Jan-08-24 07:05AM
Dec-22-23 09:01AM
Nov-29-23 07:05AM
Nov-16-23 09:55AM
Nov-09-23 04:46PM
Nov-08-23 04:42PM
Nov-07-23 07:05AM
Nov-03-23 06:53PM
Nov-01-23 07:05AM
Oct-30-23 07:05AM
Oct-05-23 07:05AM
Oct-03-23 04:05PM
Sep-26-23 07:05AM
Sep-05-23 07:05AM
Aug-30-23 07:05AM
Aug-23-23 04:05PM
Aug-02-23 05:55PM
Aug-01-23 04:05PM
Jul-26-23 07:05AM
Jul-24-23 04:05PM
Jul-11-23 07:05AM
Jul-01-23 10:09AM
Jun-27-23 07:05AM
Jun-21-23 08:00PM
Jun-20-23 08:00AM
Jun-04-23 09:15AM
Jun-01-23 07:05AM
May-23-23 07:05AM
May-22-23 07:05AM
May-16-23 05:52PM
May-08-23 07:05AM
May-04-23 06:44AM
May-03-23 05:55PM
May-02-23 04:53PM
Apr-26-23 08:00PM
Apr-18-23 07:05AM
Apr-15-23 08:20AM
Apr-11-23 07:05AM
Mar-08-23 07:05AM
Mar-05-23 07:19AM
Mar-02-23 05:51AM
Feb-28-23 08:25PM
Feb-24-23 09:20AM
Feb-22-23 03:00PM
Feb-21-23 07:05AM
Feb-17-23 07:05AM
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mills Kenneth T.President and CEOMay 14 '24Option Exercise3.7615,00056,400423,035May 16 05:06 PM
Mills Kenneth T.President and CEOMay 14 '24Sale15.8115,000237,222408,035May 16 05:06 PM
Mills Kenneth T.President and CEOApr 15 '24Option Exercise3.7615,00056,400423,035Apr 17 05:05 PM
Mills Kenneth T.President and CEOApr 15 '24Sale18.1915,000272,871408,035Apr 17 05:05 PM
Vasista VittalChief Financial OfficerMar 19 '24Option Exercise3.7620,04175,354246,534Mar 21 05:20 PM
Mills Kenneth T.President and CEOMar 14 '24Option Exercise3.7615,00056,400423,035Mar 18 05:03 PM
Mills Kenneth T.President and CEOMar 14 '24Sale21.8615,000327,942408,035Mar 18 05:03 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Option Exercise22.2512,878286,536120,070Mar 07 06:05 PM
PAKOLA STEVEChief Medical OfficerMar 05 '24Sale28.3612,878365,220107,192Mar 07 06:05 PM
Mills Kenneth T.President and CEOFeb 14 '24Option Exercise3.7615,00056,400423,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOFeb 14 '24Sale16.7615,000251,349408,035Feb 16 06:28 PM
Mills Kenneth T.President and CEOJan 16 '24Option Exercise3.7645,000169,200453,035Jan 18 06:39 PM
Mills Kenneth T.President and CEOJan 16 '24Sale15.1845,000682,992408,035Jan 18 06:39 PM
PAKOLA STEVEChief Medical OfficerJan 03 '24Sale17.3917,237299,789107,192Jan 04 04:23 PM
Mills Kenneth T.President and CEODec 19 '23Option Exercise3.6645,000164,835400,289Dec 21 01:38 PM
Mills Kenneth T.President and CEODec 19 '23Sale19.6845,000885,825355,289Dec 21 01:38 PM
Vasista VittalChief Financial OfficerMay 31 '23Option Exercise0.8535,00029,750215,001Jun 02 04:12 PM